Synonyms: MEDI-4920 | MEDI4920 | VIB 4920 | VIB-4920 | VIB4920
Compound class:
Peptide
Comment: Dazodalibep (VIB4920, formerly MEDI4920) is a fusion protein that is designed to bind to and neutralise the biological actions of the CD40 ligand (CD40L) [1-2]. Structurally dazodalibep contains two tandem human Tn3 tenascin C modules (that bind CD40L [3]) linked to human serum albumin. Previous studies have demonstrated that anti-CD40L antibodies can cause thromboembolic adverse events that arise through antibody Fc-mediated cross-linking between FcγRIIa and CD40L on platelets. The dazodalibep Fc negative fusion protein approach was initiated to mitigate these platelet-related safety issues.
|
Classification | |
Compound class | Peptide |
International Nonproprietary Names | |
INN number | INN |
11399 | dazodalibep |
Synonyms |
MEDI-4920 | MEDI4920 | VIB 4920 | VIB-4920 | VIB4920 |
Database Links | |
GtoPdb PubChem SID | 500839863 |
Search PubMed clinical trials | dazodalibep |
Search PubMed titles | dazodalibep |
Search PubMed titles/abstracts | dazodalibep |